Michael H. Davidson
Chief Executive Officer at NewAmsterdam Pharma Company; Director at Silence Therapeutics; Director at Lisata Therapeutics.
- Rank
- 4944th of 14,644
- Companies held
- 4
- Largest holding
- NAMS, 98.7% of total
- Latest SEC filing
- Sep 14, 2026
What the $21.3M is made of
Holdings counted
All filings on SEC.gov| Company | How held | Shares | Price | Value | Share of total | Reported |
|---|---|---|---|---|---|---|
| NewAmsterdam Pharma Company NAMS Ordinary Shares | Directly | 792,923 | $19.51 | $15.5M | 72.6% | Form 4, Sep 14, 2026 |
| NewAmsterdam Pharma Company NAMS Ordinary Shares | Through Michael H. Davidson 2026 Grantor Retained Annuity Trust | 285,715 | $19.51 | $5.6M | 26.1% | Form 4, Sep 14, 2026 |
| Silence Therapeutics SLN Ordinary Shares | Directly | 12,993 | $19.81 | $257K | 1.2% | Form 3, Jan 2, 2025 |
| Lisata Therapeutics LSTA Common Stock | Directly | 13,984 split-adjusted | $0.91 | $13K | 0.1% | Form 4, Jan 10, 2022 |
| Tenax Therapeutics TENX Common Stock | Directly | 2,881 | $1.39 | $4K | 0.0% | Form 4, Jan 9, 2026 |
Share counts are the amounts Michael H. Davidson reported owning after each line of their latest filing for that company, adjusted for any later stock splits. Values use the latest price. Methodology.
Open-market trades, last 12 months
| Date | Trade | Company | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Bought | NAMS | 10,000 | $22.65 | $227K | View |
| Mar 2, 2026 | Sold | NAMS | 443,707 | $33.25 | $14.8M | View |
| Feb 26, 2026 | Sold | NAMS | 165,408 | $33.63 | $5.6M | View |
| Feb 26, 2026 | Sold | NAMS | 17,924 | $34.44 | $617K | View |
| Feb 25, 2026 | Sold | NAMS | 46,517 | $35.11 | $1.6M | View |
| Feb 25, 2026 | Sold | NAMS | 10,436 | $35.96 | $375K | View |
| Feb 25, 2026 | Sold | NAMS | 1,300 | $36.68 | $48K | View |
| Feb 24, 2026 | Sold | NAMS | 61,547 | $36.13 | $2.2M | View |
| Feb 24, 2026 | Sold | NAMS | 3,161 | $36.46 | $115K | View |
| Jan 7, 2026 | Sold | NAMS | 11,582 | — | — | View |
Nearby on the list
Full list| Rank | Name | Stock holdings |
|---|---|---|
| 4941 | Jesse C. Crawford Director, Crawford &. Peachtree Corners, GA | $21.3M |
| 4942 | Aurelien Pierre Leon Nolf Chief Financial Officer, Navan. Palo Alto, CA | $21.3M |
| 4943 | Daniel R. Needham Executive Vice President, Nucor. Charlotte, NC | $21.3M |
| 4944 | Michael H. Davidson Chief Executive Officer, NewAmsterdam Pharma Company | $21.3M |
| 4945 | Christopher A. O.'Herlihy President & CEO, Illinois Tool Works. Glenview, IL | $21.3M |
| 4946 | Michael A. Pizzi Head Technology & Operations, Morgan Stanley. New York, NY | $21.3M |
| 4947 | Lisa Sanfilippo Director, John B. Sanfilippo & Son. Elgin, IL | $21.3M |
Other NewAmsterdam Pharma Company insiders
All NAMS insiders- William Lewis$202KDirector. #1817 overall
- John W. Smither$171KDirector. #12736 overall
Questions
How much stock does Michael H. Davidson own?
Michael H. Davidson holds $21,318,348 in listed stock based on SEC filings and current prices, mostly NewAmsterdam Pharma Company (NAMS). That ranks 4944th on the Stock Rich List.
Is this Michael H. Davidson's net worth?
No. It counts only listed shares reported on SEC Forms 3, 4 and 5. Cash, private companies, real estate, options and holdings that don't need to be reported are not included, so total net worth is likely different.
When did Michael H. Davidson last buy or sell stock?
The most recent open-market trade on file is a purchase of 10,000 NAMS shares on Sep 14, 2026 at $22.65.